Avantor, Inc. (AVTR) Stock Price & Analysis
Avantor, Inc. (AVTR) closed at USD 17.15 on Thursday, October 22, 2026, down 0.64% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 17.26; the Oct 22, 2026 session ranged USD 16.97–17.45 on volume of 12,740,458 shares. Market capitalization is $11.60B, with a 52-week range of USD 7.27–17.45 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AVTR.md
Key facts (AVTR)
- Last four reported quarters (through Jun 30, 2026): revenue $6.56B, net income -$578M (-8.8% margin), free cash flow $455M (SEC filings).
- 5 of 80 tracked superinvestors hold AVTR (13F, Q2 2026): 0 new, 5 added, 0 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $287K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (15 analysts), mean target USD 15.5 (range 13–19).
- Total return with dividends: 1Y +10.9% vs S&P 500 +14.9%; 5Y -55.4% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 0.21, revenue estimate $1.64B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AVTR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B | $6.56B |
| Gross profit | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B | — |
| Operating income | $972M | $1.13B | $696M | $1.08B | -$246M | -$301M |
| Net income | $573M | $687M | $321M | $712M | -$530M | -$578M |
| EPS (diluted) | $0.85 | $1.01 | $0.47 | $1.04 | -$0.78 | — |
| Free cash flow | $843M | $710M | $724M | $692M | $495M | $455M |
| Gross margin | 33.9% | 34.6% | 33.9% | 33.6% | 32.7% | — |
| Operating margin | 13.2% | 15.0% | 10.0% | 16.0% | -3.8% | -4.6% |
| Net margin | 7.8% | 9.1% | 4.6% | 10.5% | -8.1% | -8.8% |
| Revenue growth | +15.5% | +1.7% | -7.3% | -2.6% | -3.4% | — |
| Cash + short-term investments | $302M | $373M | $263M | $262M | $365M | — |
| Total debt | $7.02B | $6.29B | $5.54B | $4.06B | $3.95B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (AVTR)
P/S 1.8x · EV/EBITDA 127.8x · EV/Sales 2.3x · P/FCF 25.5x · P/B 2.1x · FCF yield 3.92% · Earnings yield -4.98% · Net debt $3.39B · EV $15.0B
P/E at fiscal year-ends: Dec 2024 20.2x, Dec 2023 48.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (AVTR)
5 of 80 tracked investors hold AVTR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Greenhaven Associates | 2.82% | $244M | Added +9.0% | |
| Mason Hawkins | Southeastern Asset Management | 2.44% | $46.8M | Added +34.2% |
| First Pacific Advisors | 1.02% | $81.1M | Added +1.3% | |
| Dodge & Cox Funds | Dodge & Cox | 0.62% | $1.19B | Added +0.3% |
| Yacktman Asset Management | 0.58% | $47.2M | Added +0.5% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (AVTR)
2 purchases, $287K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-08 | Lucier Gregory T | Director | 10,000 | $83K | 8.32 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Dingemans Simon | Director | 25,000 | $204K | 8.14 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (AVTR)
Consensus Hold (mean 3.00 on a 1–5 scale), 15 analysts; mean target USD 15.5 (low 13, high 19).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Target raised | Equal-Weight | $14 → $15 |
| 2026-10-13 | TD Cowen | Target raised | Hold | $15 → $17 |
| 2026-10-07 | Barclays | Target raised | Underweight | $13 → $15 |
| 2026-09-09 | UBS | Target raised | Neutral | $10.5 → $16 |
| 2026-07-30 | Morgan Stanley | Target raised | Equal-Weight | $10 → $14 |
| 2026-07-30 | RBC Capital | Target raised | Sector Perform | $9 → $14 |
| 2026-07-30 | Stifel | Target raised | Hold | $8 → $15 |
| 2026-07-30 | Evercore ISI Group | Target raised | In-Line | $10.5 → $14 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $14 → $16 |
| 2026-07-08 | Citigroup | Target raised | Neutral | $9 → $11 |
| 2026-07-06 | Evercore ISI Group | Target raised | In-Line | $8 → $10.5 |
Total return (dividends reinvested) (AVTR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +10.9% | -55.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +11.0% | -14.9% |
| Volatility (annualized) | 51.0% | 40.9% |
| Max drawdown | -52.1% (Oct 2025→Mar 2026) | -82.4% (Dec 2021→Mar 2026) |
AVTR revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| VWR Distribution & Services | $1.24B | 73.3% | +2.7% |
| Bioscience & Medtech Products | $451.8M | 26.7% | -5.1% |
| Total revenue | $1.69B | 100% | — |
AVTR revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Proprietary | $880.4M | 52.0% | -1.5% |
| Third-party | $811.9M | 48.0% | +2.8% |
| Total revenue | $1.69B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name AVTR in their SEC reports
| Relationship to AVTR | Company | Filing | Sentence |
|---|---|---|---|
| customer | ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | 10-K Feb 27, 2026 | “In particular, we obtain NuSil brand medical-grade silicone from Avantor, Inc. (formerly NuSil Technology LLC), or Avantor, which is a sole-source supplier of such products to the majority of the silicone breast implant industry.” |
AVTR customer concentration
In the period ended Dec 31, 2025, a single direct customer accounted for 5% of revenue, per the company's 10-K filed Feb 11, 2026. The company does not name it.
AVTR company outlook (results filed Jul 29, 2026)
- “Avantor updates its fiscal 2026 financial guidance.”
- “Fiscal 2026 guidance (as of April 29, 2026) Updated Fiscal 2026 guidance (as of July 29, 2026) Organic revenue growth (1) -2.5% to -0.5% -0.5% to +0.5% Adjusted EBITDA margin (1) 14.8% to 15.3% 14.8% to 15.3% Adjusted EPS (1) $0.77 to $0.83 $0.80 to $0.83 Free cash flow (1)(2) $500M to $550M $500M to $550M (1) Non-GAAP measure (definitions and/or reconciliations below).”
- “We are unable to provide a reconciliation of the non-GAAP measures provided in our full-year 2026 guidance without unreasonable effort because of the difficulty in forecasting and quantifying certain amounts and adjustment items with a reasonable degree of certainty including net income, restructuring charges, foreign currency exchange gains and losses and income tax expense.”
Quoted word-for-word from the SEC 8-K results press release.
AVTR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.21 | $0.20 | +2.0% | $1.64B | 15 |
| Next quarter (ends Dec 2026) | $0.23 | $0.23 | -0.9% | $1.68B | 14 |
| Current fiscal year (ends Dec 2026) | $0.81 | $0.79 | +3.0% | $6.59B | 15 |
| Next fiscal year (ends Dec 2027) | $0.88 | $0.85 | +2.9% | $6.74B | 15 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 17.15 |
|---|---|
| Change | ▼ 0.64% (down) |
| Previous Close | USD 17.26 |
| Open | USD 17.29 |
| Day Range | USD 16.97 – 17.45 |
| 52-Week Range | USD 7.27 – 17.45 |
| Volume | 12,740,458 shares |
| Market Cap | $11.60B |
| Exchange | NYQ |
Technical Analysis (AVTR)
Nexqual's technical model rates AVTR "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 71.29 (overbought) |
| vs SMA50 | Above (USD 15.12) |
| MACD | 0.53 (positive) |
Analyst Ratings (AVTR)
Wall Street analysts rate AVTR "Hold" based on 15 analysts, with a mean price target of USD 15.5 (range USD 13–19), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 15.5 |
| High Target | USD 19 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 2 / 12 / 1 |
Earnings (AVTR)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.21 |
| Revenue Estimate | $1.64B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.21 vs est 0.19 ▲ beat |
| 2026-03-31 | USD 0.17 vs est 0.16 ▲ beat |
| 2025-12-31 | USD 0.22 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.22 vs est 0.23 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (AVTR)
| Total Revenue | $6.56B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.50% |
| Gross Margin | +31.82% |
| Operating Margin | +7.16% |
| Profit Margin | -8.81% |
| ROE | -9.70% |
| Debt / Equity | 0.66 |
| Current Ratio | 1.78 |
| Total Cash | $306.80M |
| Total Debt | $3.70B |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Ownership (AVTR)
| Insider Ownership | +1.53% |
|---|---|
| Institutional Ownership | +105.76% |
| Shares Outstanding | 676.36M |
| Float | 657.81M |
| Short % of Float | +7.06% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (AVTR)
Avantor, Inc. is led by Emmanuel Ligner, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| President, CEO & Director | Emmanuel Ligner |
|---|---|
| President of Laboratory Solutions | Corey D. Walker |
| Executive Vice President of Bioscience Production | Benoit Gourdier |
| Executive VP & CFO | Todd W. Garner |
| Executive VP & COO | Mary Blenn |
Major Backers & Investors (AVTR)
Notable institutional backers of Avantor, Inc. include Dodge & Cox Inc., Greenhaven Associates, Inc., Engine Capital Management, LP, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 17.75% |
| Greenhaven Associates, Inc. | 3.64% |
| Engine Capital Management, LP | 2.94% |
| Barrow, Hanley Mewhinney & Strauss, LLC | 2.92% |
| New Mountain Capital, L.L.C. | 2.07% |
| Bridge Builder Trust-Bridge Builder Large Cap Value Fund | 1.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.39% |
| Vanguard Group | 9.18% |
| State Street | 3.19% |
| Dimensional Fund Advisors | 3.02% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Avantor, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- The following charts present the approximate mix of net sales for each of these groups during 2025: Our portfolio includes a comprehensive range of products and services that allows us to create customized and integrated solutions for our customers.
- Our proprietary brands have been specified and trusted for decades.
- At Avantor, everything we do is tied to our unique mission of setting science in motion to create a better world.
- Our customer-centric innovation model enables us to provide solutions for some of the most demanding applications, and we leverage our comprehensive offering and access to early-stage research to identify and develop content and solutions that ultimately become specified into our customers' approved production platforms.
Legal & Regulatory Risks (Item 1A, quoted)
- We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies, and our failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition.
- Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents or business partners.
- We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in sales to these customers or penalties.
- We are subject to environmental, health and safety laws and regulations, and costs to comply with such laws and regulations, or any liability or obligation imposed under such laws or regulations, could negatively impact our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COO | The Cooper Companies, Inc. | USD 61.65 | ▲ 4.54% |
| RGEN | Repligen Corporation | USD 178.71 | ▼ 0.72% |
| ALGN | Align Technology, Inc. | USD 155.51 | ▲ 2.74% |
| BAX | Baxter International Inc. | USD 25.65 | ▲ 3.85% |
| SOLV | Solventum Corporation | USD 87.45 | ▲ 0.9% |
| ATR | AptarGroup, Inc. | USD 128.1 | ▲ 1.97% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt